CORDIS provides links to public deliverables and publications of HORIZON projects.
Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .
Deliverables
"Dissemination plan. I will present the research findings at the CNC (weekly) seminars series (oral communication, one per year) and at the following international conferences: Spanish-Portuguese Local Chapter of the Controlled Release Society – CRS (SPLC-CRS, 2022; oral communication; with 200 participants in 2018); Portuguese Association for Cancer Research (ASPIC, 2023; oral communication; with 700 participants in 2020) and a poster at the Annual Meeting of the American Association for Cancer Research, AACR (2023; with, approximately, 22500 participants in 2019). I will also provide 1 lecture/year at the master course on Pharmaceutical Biotechnology, MPB (Faculty of Pharmacy, UC, FPUC) and at the advanced course on Principles and Practice in Drug Development, PPDD (from CNC PhD program on Biomedicine and Experimental Biology), both averaging 20-30 students and coordinated by the PI. I expect to publish (all in green open-access) 2 original manuscripts (#1 on WPs1&2, at ACS Nano, IF: 15.881; and #2 on WPs3&4, at Nano Today, IF: 20.722), and after patent (PCT) submission. One review article (#3, including experience arising from WPs1-5) is also expected to be published at Trends in Biotechnology (IF: 14.343) on the translational challenges of RNA-containing LNPs for cancer therapy. This plan will impact dissemination among other peers (users), expert researchers (users) and clinicians (end-users), increasing awareness on the need of a targeted treatment for MPM, as well as educational training of, at least, 2 master students (TABLE 1). The 6-month period at Bluepharma will contribute to successfully start bridging the gap with the market.Exploitation plan. Novel intellectual property will be generated on a novel immunotherapy NCL-LNP(saIRF5/IL-12-saRNAs) for the treatment of MPM, properly framed after performing a freedom-to-operate. Good research practices in record keeping and pre-publication reviews will be observed to avoid value leakage and secure IP. I will engage in IP management training (Section 1.3). The patent filling (month 14) will be performed through the Technology Transfer Office (UC Business), with the supervisor involvement (has successfully licensed 5/9 patents). Companies in the field of nucleic acid delivery and/or complex injectables (Pfizer, BioNTech, Moderna, Acuitas, Alnylam or Bluepharma) are potential clients for the new IP. From the company and society perspective, overall (direct) impact is expected upon addressing an unmet medical need in MPM, associated with a novel form of immunotherapy, with replication potential to other nucleolin-overexpressing tumors. A license deal will be negotiatedby UC, based on upfront and milestones payments, plus royalties on annual sales.Communication activities. I will take advantage of CNC/UC’s dedicated Science Communication Office (SCO) with well-established dissemination/communication channels, including media and broad end-users’ (TV, radio, newspapers, blogs and social networks) and engage in relevant communication and outreach activities to raiseawareness about MPM, and contribute to the development of scientific and technological literacy and culture by the public: (1) Design and propose a MPM thematic activity to be presented in the 2022 and 2023 editions of the European Researchers’ Night, organized by CNC in collaboration with the UC-Science Museum and IEC - an institute promoting scientific education and literacy in the rural community of the region (www.educacao-ecidadania.pt); (2) Participate in the “Open Days” and “Science & Technology Week” (open-doors initiatives), welcoming high-school student visits to the Tumor Microenvironment and Targeted Therapies group laboratories; (3) Devise an activity (e.g., leaflet, cartoon, video) targeting MPM risk factors/groups (e.g., asbestos) to be released on the World Cancer Day (4th February) through the appropriate CNC-channels (YouTube, Facebook, institutional webpage (www.cnbc.pt/outreach/"
Data Management Plan (opens in new window)Once the essential IP rightsinterests have been secured project publications will be available in Green open access and the analogous holds true for the generated materials technologies and overall data following FAIR guidelines UC features its own scientific production repository Estudo Geral and we will use an online data repository such as Zenodo
Searching for OpenAIRE data...
There was an error trying to search data from OpenAIRE
No results available